SNRI vs. SSRI: Why the Right Antidepressant Is the One That Fits, Not the One That's Stronger

Your prescriber mentions an SSRI, or maybe an SNRI, and suddenly it feels like you’re supposed to pick the right answer. If you’ve already tried one and it didn’t feel right, the question gets louder: was it the wrong kind of medication, or just the wrong match for you?

Here’s the mechanism underneath. After a nerve cell releases a chemical messenger, a transporter pulls it back in to be reused. SSRIs slow that recycling for serotonin, and SNRIs slow it for both serotonin and norepinephrine, a messenger also involved in alertness and blood pressure. Choosing between them takes precision, because that one extra target changes the side-effect picture more than it changes your odds of feeling better.

The standard approach is well established. ACP’s 2023 guideline recommends either cognitive behavioral therapy or a second-generation antidepressant, a group that includes both SSRIs and SNRIs, as initial treatment for moderate to severe depression. Both classes have decades of trials behind them, and a Lancet meta-analysis of 522 trials found all 21 antidepressants it studied more effective than placebo. The results are real, and the science is well established.

But the evidence doesn’t crown one class as stronger, and at Siggy we’d rather match the medication to your symptoms and your body than pick a winner on paper.

That matching is the real decision. It means looking at what else is going on, like chronic pain, blood pressure, how you handle side effects, and how easy the medication will be to stop someday, then choosing the class that fits and tracking how it works. An AHRQ-funded meta-analysis of 234 studies found no clinically relevant differences in efficacy among second-generation antidepressants and concluded that differences in onset and side effects can guide the choice. That’s a choice grounded in pharmacology, and the trial evidence supports it.

What This Page Covers

• What Is the Actual Difference Between an SSRI and an SNRI?
• Is One More Effective Than the Other?
• How Do They Compare for Anxiety?
• When Might an SNRI Make More Sense?
• How Do the Side Effects Differ?
• What About Stopping or Switching?
• How Siggy Fits In
• Choose for Fit, Then Track How It Goes

What Is the Actual Difference Between an SSRI and an SNRI?

The difference is the number of messengers each class targets. Common SSRIs include sertraline, escitalopram, fluoxetine, citalopram, and paroxetine. Common SNRIs include venlafaxine, desvenlafaxine, duloxetine, and levomilnacipran. MedlinePlus’s venlafaxine guide describes SNRIs as working by increasing the amounts of serotonin and norepinephrine in the brain.

SNRIs also differ from one another more than their shared label suggests. A pharmacology review notes that they vary in approved uses, half-lives, metabolism, and how strongly each one acts on serotonin compared with norepinephrine. That’s one reason a rough experience with one SNRI doesn’t automatically rule out another.

Is One More Effective Than the Other?

On average, the difference is small. In a 2007 meta-analysis of 93 trials with 17,036 people, antidepressants that act on both serotonin and norepinephrine produced response in 63.6% of patients, compared with 59.3% for SSRIs. The authors calculated that nearly 24 people would need to take a dual-action drug instead of an SSRI for one additional person to respond, which falls well short of the number needed to treat of 10 that the UK’s NICE has suggested as a mark of clinical significance. That dual-action group included venlafaxine, duloxetine, and milnacipran, but also mirtazapine and other non-SNRI drugs, and duloxetine on its own showed no advantage.

The larger 2011 AHRQ-funded review reached a similar conclusion, finding no efficacy differences in subgroups based on age, sex, ethnicity, accompanying symptoms, or other conditions. Its authors noted that individual drugs differed in onset of action, side effects, and some quality-of-life measures. For most people, those differences are where the real choice lives.

How Do They Compare for Anxiety?

Both classes treat anxiety. In a 2019 meta-analysis of 89 trials and 25,441 people with generalized anxiety disorder, duloxetine, venlafaxine, and escitalopram were each more effective than placebo with relatively good acceptability. Sertraline was also effective and well tolerated, though that finding rested on smaller samples. Paroxetine worked but was poorly tolerated compared with placebo.

That mix of SSRIs and SNRIs near the top is the point. For anxiety, the better question is which specific medication you’re likely to tolerate. If anxiety is your main concern, our comparison of Effexor vs. Lexapro looks at one common SNRI and SSRI side by side.

When Might an SNRI Make More Sense?

Chronic pain is the clearest case. Duloxetine’s MedlinePlus guide lists depression and generalized anxiety disorder alongside pain from diabetic nerve damage, fibromyalgia, and ongoing bone or muscle pain. In a Cochrane review of 18 trials with 6,407 participants, duloxetine 60 mg daily was effective for painful diabetic neuropathy, with a number needed to treat of 5 for one extra person to get at least 50% pain relief over 12 weeks. The review rated evidence in fibromyalgia as lower quality and noted that most trials were sponsored by the manufacturer.

The reverse can also be true. The venlafaxine label advises controlling high blood pressure before starting, and MedlinePlus asks you to tell your doctor about heavy drinking or liver disease before taking duloxetine. If either applies, or if stopping a past antidepressant was rough, an SSRI may be the simpler starting point. ACP’s guideline also says the choice should reflect your specific symptoms, other health conditions, and other medications. In practice, that means your full history shapes the decision: pain, sleep, energy, blood pressure, past medication trials, and what you’re hoping changes first.

How Do the Side Effects Differ?

Much of the side-effect profile overlaps. NIMH’s medications guide lists upset stomach, headache, and sexual dysfunction as common side effects of SSRIs and other antidepressants, usually mild and fading with time, and notes that people under 25 may have an increase in suicidal thoughts, especially in the first weeks or after a dose change. The table below summarizes key similarities and differences using the anxiety and efficacy reviews above, NIMH, FDA’s venlafaxine label, and a 2024 discontinuation meta-analysis.

Factor	SSRIs	SNRIs
Main target	Serotonin	Serotonin and norepinephrine
Depression efficacy	Similar overall	Similar overall
Generalized anxiety	Escitalopram, sertraline effective	Duloxetine, venlafaxine effective
Common side effects	Upset stomach, headache, sexual	Similar, plus possible blood pressure rise
More frequent discontinuation symptoms	Escitalopram	Venlafaxine, desvenlafaxine

Blood pressure is the most practical difference. The venlafaxine label reports dose-related increases in systolic and diastolic blood pressure, including cases of sustained hypertension, and advises checking blood pressure before and during treatment. MedlinePlus gives the same advice for duloxetine, and also lists liver warning signs, such as yellowing skin or dark urine, and cautions that alcohol can increase the risk of serious side effects.

If you notice new or worsening thoughts of suicide, agitation, or hopelessness on any antidepressant, call or text 988, or call 911 in an emergency.

What About Stopping or Switching?

How a medication ends matters as much as how it starts. The 2024 meta-analysis of 79 studies found at least one discontinuation symptom in 31% of people stopping an antidepressant, compared with 17% stopping placebo, and estimated that about 1 in 6 to 7 people have symptoms caused by stopping. Desvenlafaxine, venlafaxine, imipramine, and escitalopram were linked with more frequent symptoms. Imipramine, paroxetine, and either desvenlafaxine or venlafaxine were linked with more severe ones.

Venlafaxine’s short half-life is part of the story. Its label lists an elimination half-life of about 5 hours for venlafaxine and 11 hours for its active metabolite, recommends gradual dose reduction instead of abrupt stopping, and notes that some people need several months to taper.

Switching is a reasonable next step. ACP lists switching to a different second-generation antidepressant, or adding another treatment, as options when the first one doesn’t help at an adequate dose. Our guide to what to do when an antidepressant isn’t working at 8 weeks walks through that decision.

How Siggy Fits In

Siggy’s licensed prescribers diagnose and treat the full range of mental health conditions, and SSRIs and SNRIs are both options. Whether an SNRI belongs in your plan is a decision a licensed prescriber makes after reviewing your full intake, including pain, blood pressure, other medications, and what you’ve tried before.

The anonymous intake asks for no name, email, or account, so you can describe your symptoms and past medication experiences in your own words. You’ll get a downloadable summary you can keep or share with any clinician, so the next person who helps you starts with your history instead of a blank page.

Siggy isn’t an emergency service. If you’re in crisis, call 911 or call or text 988. This article is for education only and isn’t a substitute for personal medical advice. It reflects sources available as of October 2026.

Choose for Fit, Then Track How It Goes

SSRIs and SNRIs work about equally well for depression, so the decision usually comes down to fit: chronic pain may tip things toward an SNRI, while blood pressure concerns or a history of rough discontinuation may tip things the other way. Whatever you start, the first weeks tell you whether it’s the right match, and our guide on how long antidepressants take to work explains what to expect. Start your anonymous intake and tell us what you’ve tried, what helped, and what didn’t. It’s free, a real doctor reviews every clinical decision, and the summary is yours to share with whoever helps you next.